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Abstract
Background Sarcopenia is deﬁned as the age-related loss of skeletal muscle mass and function. While all humans lose
muscle with age, 2–5% of elderly adults develop functional consequences (disabilities). The aim of this study was to investigate
muscle myogenesis in healthy elderly adults, with or without sarcopenia, compared with middle-aged controls using both
in vivo and in vitro approaches to explore potential biomarker or causative molecular pathways associated with sarcopenic
versus non-sarcopenic skeletal muscle phenotypes during ageing.
Methods Biomarkers of multiple molecular pathways associated with muscle regeneration were analysed using quantitative
polymerase chain reaction in quadriceps muscle samples obtained from healthy elderly sarcopenic (HSE, n = 7) or
non-sarcopenic (HENS, n = 21) and healthy middle-aged control (HMC, n = 22) groups. An in vitro system of myogenesis (using
myoblasts from human donors aged 17–83 years) was used to mimic the environmental challenges of muscle regeneration over
time.
Results The muscle biopsies showed evidence of satellite cell activation in HENS (Pax3, P < 0.01, Pax7, P < 0.0001) com-
pared with HMC. Early myogenesis markers Myogenic Differentiation 1 (MyoD1) and Myogenic factor 5 (Myf5)
(P < 0.0001) and the late myogenesis marker myogenin (MyoG) (P < 0.01) were increased in HENS. In addition, there was
a 30-fold upregulation of TNF-α in HENS compared with HMC (P < 0.0001). The in vitro system demonstrated age-related up-
regulation of pro-inﬂammatory cytokines (2-fold upregulation of interleukin (IL)-6, IL-8 mRNA, increased secretion of tumor
necrosis factor-α (TNF-α) and IL-6, all P < 0.05) associated with impaired kinetics of myotube differentiation.
The HSE biopsy samples showed satellite cell activation (Pax7, P < 0.05) compared with HMC. However, no signiﬁcant upreg-
ulation of the early myogenesis (MyoD and Myf5) markers was evident; only the late myogenesis marker myogenin was up-
regulated (P < 0.05).
Higher activation of the oxidative stress pathway was found in HENS compared with the HSE group. In contrast, there was 10-fold
higher upregulation of HSPA1A a stress-induced chaperone acting uponmisfolded proteins in HSE compared with the HENS group.
Conclusions Both pathological and adaptive processes are active in skeletalmuscle during healthy ageing.Muscle regeneration
pathways are activated during healthy ageing, but there is evidence of dysregulation in sarcopenia. In addition, increased cellular
stress, with an impaired oxidative-stress andmis-folded protein response (HSPA1A), may be associated with the development of
sarcopenia. The in vitro system of young and old myoblasts replicated some of the differences between young and old muscle.
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Introduction
Sarcopenia is deﬁned as an age-related loss of skeletal muscle
mass and function,2,3 which may develop in the absence of
overt disease. Age-related muscle loss is accelerated by
reduced physical activity, as well as by acute or chronic disease.
Age-related sarcopenia and other muscle atrophy conditions
share common functional consequences, including a loss of
muscle strength and power, and are major causes of mobility
disability.4 The severity and functional consequences of
sarcopenia varywidely inolder adultsof thesamechronological
age, and the molecular processes underpinning healthy ageing
without sarcopenia are still notwell understood.Muscle regen-
eration,5–7 senescence,8 inﬂammation,9,10 oxidative stress,11
and apoptosis12,13 are all cellular processes that inﬂuence
musclemass and thereforemay play a role in the development
orprotection fromsarcopeniaduringageing.14,15Accumulating
evidence suggests that these complex cellular processes, along-
side increased cytokine activity, play a role in satellite cell acti-
vation and differentiation during muscle ﬁbre repair and
remodelling inhumans.16,17Therehavebeenpriorstudiescom-
paring skeletal muscle in healthy elderly adults with thosewith
pathologies including cancer,18 but studies in healthy elderly
adults without sarcopenia, which assess multiple biomarkers
of muscle regeneration and underlying cellular processes in
tandem in the same human muscle biopsies are lacking.
To study sarcopenia in vivo, researchers use animal models
of different ages e.g., Ibebunjo et al., 2013.19 Here, we focus
on the investigation of the regeneration process in healthy
ageing human muscle and the underlying multiple underlying
cellular processes including senescence, apoptosis, and
chronic inﬂammation in the muscle microenvironment utiliz-
ing both in vitro and in vivo methods. We asked whether
the development of sarcopenia in elderly adults might be
associated with dysregulation of muscle regeneration and
whether the latter might be due to impaired defence mecha-
nisms against increasing oxidative stress. The aim of this
study was ﬁrst, to establish whether myogenesis is altered
in healthy elderly adults with or without sarcopenia,
compared with healthy middle-aged controls (HMCs).
Secondly, we explored molecular pathways underpinning
differences in muscle phenotypes during healthy ageing.
Methods
Participants
All participants gave written informed consent prior to entry
into the study. All procedures were approved by the NHS
Lothian and Maastricht University Hospital local research
Ethics Committees. The study conformed to the standards
set by the Declaration of Helsinki.
Healthy Elderly [Healthy Elderly Sarcopenic (HSE); Healthy
Elderly Non-Sarcopenic (HENS)]: 30 participants aged 79 years
or over were recruited via advertisements. They were deﬁned
as healthy on the basis of their responses to previously
published health selection criteria.20 None were engaged in
any form of physical training. All participants were screened
using body composition analysis by Dual-energy X-ray absorp-
tiometry scanning and were classiﬁed as either HSE or HENS
according to established cut-offs based on the relative skele-
tal muscle index.21 Muscle biopsies of 28 volunteers were
available for analyses (HSE; n = 7 and HENS; n = 21).
HMC: 22 participants were recruited via advertisements.
Participants had no recent weight loss or any common dis-
ease associated with cachexia (cancer, severe COPD, conges-
tive heart failure, active infectious disease). Individuals
taking hormones or continual oral steroids were excluded.
Measurement of C-reactive protein
C-reactive protein was measured in serum using an auto-
mated blood chemistry analyser technique (Abbott TDX).
Dual-energy X-ray absorptiometry body
composition analysis (Healthy Elderly
Non-Sarcopenic, Healthy Elderly Sarcopenic, and
Healthy Middle-aged Control)
Dual-energy X-ray absorptiometry [DPX-L; Lunar Radiation
Corp (HMC) and Hologic QDR4500A (HSE; HENS)] was used
to measure different body compartments (i.e., fat mass, lean
mass, and bone mineral content). Muscle biopsy.
A Bergstrom needle muscle biopsy was obtained from the
lateral mass of the quadriceps under local anaesthetic, after a
12-h overnight fast. The biopsy was cleaned of gross blood
contamination and snap frozen in liquid nitrogen and stored
at 80 °C.
Total RNA isolation
Tissue was homogenized in Qiazol (Qiagen, UK) reagent using
a Polytron PT1200E (Kinematica AG, Switzerland). Total RNA
was extracted using miRNEasy columns (Qiagen, UK) as di-
rected by the manufacturer, with an on-column DNAse diges-
tion step. RNA was quantiﬁed using the Nanodrop instrument
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(Labtech Intl, UK). Quality and purity of RNA was examined
using 260/280 and 260/230 ratios. The Agilent bioanalyzer
(Agilent, UK) was used to assess RNA integrity using previously
published protocols.22 All samples had 260/280 ratios above
1.8, and RNA integrity number scores above 7.5.
Quantitative polymerase chain reaction
The High Capacity RNA-to-cDNA kit (Applied Biosystems, UK)
was used to convert 1 μg of RNA to cDNA following the
manufacturer’s directions. The quantitative validation of
the expression of selected genes was performed using
quantitative polymerase chain reaction (QPCR) (Applied
Biosystems StepOne Real-Time PCR Systems) using custom
PrimerDesign primers and applying the Sybr Green PCR master
mix (Applied Biosystems, Foster City, CA, USA), following the
manufacturer’s protocol. Reactions were run in triplicate on a
StepOne Plus instrument (Applied Biosystems, UK). Running
conditions were 95 °C 10 min followed by 40 cycles of 95 °C
15 s and 60 °C 60 s. Ampliﬁcation was performed for each cDNA
(20 ng) sample in triplicate. The fold change in expression of
the target gene relative to the internal control gene (SDHA,
CYC1, and GAPDH) was assessed. QPCR data were presented
as the fold-change in gene expression normalized to the aver-
age value of two common endogenous reference genes and
relative to the control (HMC muscle samples). See supplied
supporting information Table 1 for QPCR primers.
Identiﬁcation of suitable reference genes
We utilized the geNorm Housekeeping Gene Selection Kit
(PrimerDesign) to evaluate 12 commonly used housekeeping
genes in HENS, HSE, and HMC muscle. Reference genes
tested were 18S (18S ribosomal RNA subunit), β-Actin
(beta-actin), ATP5b (ATP synthase subunit 5b), B2M (beta-2
microglobulin), TOP1 (topoisomerase 1), CYC1 (cyclin D1),
EiIF4a2 (eukaryotic initiation factor 4a2), GAPDH (glyceralde-
hyde-3-phosphate dehydrogenase), RPL13a (ribosomal pro-
tein L13a), SDHA (succinate dehydrogenase complex,
subunit A), UBC (ubiquitin C), and YHWAZ (phospholipase
A2). The geNorm output ranked the candidate reference
gene according to their expression stability (M). Using this
approach, we identiﬁed 3 housekeeping genes (CYC1, SDHA,
and GAPDH) as being the most stably expressed in, HSE,
HENS, and HMC groups, respectively (see Supporting Infor-
mation). These three reference genes were used in subse-
quent analyses.
Cultivation of human skeletal muscle cells
To study the age dependent phenotype in an in vitro system
we ordered primary human skeletal muscle cells (hsKMC;
Cook Myosite), obtained from donors with different ages
(aged 83 years; P101042-83 M, 73 years; P101043-73 M,
69 years; P101064-69 M, 51 years; P101061-51 M, 50 years;
P301014-50 M, 20 years; P101040-20 M, and 17 years;
P201052-17 M: See supplied supporting information Table 2
for further information). The hsKMC were cultured according
to the manufacturer’s protocol (Cook Myosite PA 15238,
USA). For the analysis, the results obtained with hsKMC are
represented in two groups younger (donor age 17–51 years)
and older (69–83 years), a categorisation that is consistent
with literature reporting an increased prevalence of
sarcopenia in adults older than 70 years.23
Fusion assay
For the fusion assays, 10 000 hsKMC cells/well were seeded
onto collagen in 96-well plates in GM supplemented with
20% FBS, 1% Gentamicin at 37 °C, 5% CO2, and 95% humidity
and grown at 37 °C for 1 day. Next day, the cells were washed
once with serum-free differentiation medium and then culti-
vated in differentiation medium supplemented with 2% heat
inactivated HES, 1% FBS, and 1% Gentamicin for 96 h at 37 °
C, 5% CO2, and 95% humidity. The fusion index was calculated
as the percentage of nuclei in myotubes (myosin heavy chain
positive stained cells) compared with the total number of
nuclei.
Determination of secreted proteins in the
supernatant of primary human skeletal muscle
cells.
Supernatants of the primary skeletal muscle cells from do-
nors of different age (17 years, 20 years, 50 years, 51 years,
69 years, 73 years, and 83 years) were taken at 48 h during
differentiation and measured using the RayBio human cyto-
kine array (AAH-CYT-G4000; RayBiotech Inc, Norcross GA,
USA) according to the manufacturer’s protocol. Cytokine ar-
rays were measured using the GenePix 4000B (Molecular De-
vices, CA, USA).
Preparation for protein extraction
Proteins were extracted from pulverized human skeletal mus-
cle cells by homogenizing the samples in the Precellys 24 sys-
tem. Brieﬂy, 300 μl of PhosphoSafe Extraction Reagent
(Millipore) was added to minced and ground human skeletal
muscle tissue (8 mg) in Precellys 24 lysing kit tubes. Tissue
was further homogenized using the high-throughput homog-
enizer Precellys 24, for 10s. After incubation on ice for 5 min,
the lysates were spun at 800xg for 5 min at 4 °C. Superna-
tants were transferred into new tubes and spun for another
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12 min at 1600xg at 4 °C. Pellets (insoluble fraction) were
stored at 80 °C until further us. Supernatants were col-
lected and protein concentrations measured using the BCA
Protein Assay Kit (Pierce) with BSA as a standard. Afterwards,
phosphatase inhibitor cocktail (Roche) was added and the
samples were stored at 80 °C until further use.
Western blots
Ten microgram of human skeletal muscle cell protein extracts
(17- and 83-year-old donor) in reducing Laemmli SDS sample
buffer were boiled for 5 min at 95 °C and then separated by
SDS-PAGE on 4–20% gradient gels (Bio-Rad, Cressier,
Switzerland), blotted to Nitrocellulose membranes (Bio-Rad)
using the Trans-Blot Turbo Transfer System (Bio-Rad),
blocked for 1 h in blocking buffer (5% non-fat milk in
Tris-buffered saline 0.05% Tween-20), incubated overnight
with primary antibody, rinsed, and incubated for 1 h with
peroxidase-conjugated goat anti-rabbit IgG at room tempera-
ture. Blots were developed using ECL (Roche, Rotkreuz,
Switzerland) or SuperSignal West Femto substrate (Thermo
Scientiﬁc, Wohlen, Switzerland) and exposed to Kodak ﬁlm
(Kodak, Rochester, NY, USA). Antibodies: phospho-p38
(THR180, Tyr182) (Novus Biologicals, Littleton, CO, USA);
p38 (Cell Signalling Technologies, Danvers, MA, USA), Tropo-
nin I skeletal fast (abcam, Cambridge, UK). Western blots
were analysed densitometrically using ImageJ software ver-
sion 1.45 (NIH, Bethesda, MD, USA; http://rsbweb.nih.gov/
ij). Band intensity of each sample was normalized to
coomassie blue stained gels.
Statistical analysis
The Graphpad prism6 software package (GraphPad Software,
Inc., La Jolla, CA, USA) was used for statistical analysis.
Statistical signiﬁcance of the quantitative polymerase chain
reaction results was assessed using non-parametric Kruskal-
Wallis tests. Statistical signiﬁcance of the Western blot data
was assessed using the Mann Whitney Test as described by
Eaton et al., 2013.24 Results were considered signiﬁcant at
P < 0.05.
Results
Participant characteristics
The characteristics of the HENS, HSE, and HMC groups are
presented in Table 1. The healthy elderly participants were
balanced in their sex distribution and had a mean age of
79 years. HENS participants had a normal BMI and had nor-
mal serum C-reactive protein. Twenty ﬁve percent (25%;
n = 7) of the elderly participants were classiﬁed as HSE. The
HMC group were, on average, nearly two decades younger
than the HENS. There was a predominance of men and aver-
age BMI was normal.
Differences between groups in early and late
myogenesis
To explore whether healthy ageing without sarcopenia was
underpinned by differences in myogenesis or muscle
generation, we measured multiple transcriptional markers
compared with middle-aged controls. The expression of
markers indicating satellite cell activation, i.e., the muscle
transcription factor Pax3 showed 4-fold (P < 0.01), and
the muscle transcription factor Pax7 a 9-fold expression
(P < 0.0001) in HENS compared with HMC (Figure 1a). The
expression of markers of early differentiation [MyoD and
Myogenic factor 5 (Myf5)] was increased (7-fold,
P < 0.0001), as well as a 6-fold (P < 0.05) elevated
expression of myogenin (MyoG), a marker of terminal differ-
entiation, detected in HENS compared with HMC (Figure 1b
and 1c). However, the muscle remodelling factor myocyte
enhancer factor-2 (Mef2) was signiﬁcantly downregulated in
HENS compared with HMC (Figure 1d).
To explore whether sarcopenia during ageing was
underpinned by differences in myogenesis or muscle
Table 1 Characteristics of all the recruited subjects. The majority of the
sarcopenic participants were male (4M: 3F)
Participants Healthy elderly (n = 28)
Healthy middle age
(n = 22)
HENS
(n = 21)
HSEb
(n = 7)
M:F 11:10 5:2 12:8 e
Age 79 (3.4) 79.3 (3.5) 61 (7) e
Weight (kg) 69 (14) 65 (8) 73 (12) e
Height (cm) 1.65 (0.09) 1.67 (0.09) 1.73 (0.10) e
BMI 25.4 (3.9) 23.3 (2.3) 24.2 (3.3) e
LBM (kg) 48.1 (10.5) 45.9 (8.4) 53.3 (9.8) e
FM (kg) 19.1 (6.7) 16.8 (4.1) 17.6 (2.1) e
ASM (kg/m2) 7.3 (1.3) 6.4 (0.9) 7.7 (1.0) e
CRP (mg/L) 3 (3) 3 (3) —
ASM, Appendicular skeletal muscle mass; CRP, C-reactive protein;
e, estimated; HENS, Healthy Elderly Non-Sarcopenic; HSE, Healthy
Elderly Sarcopenic. Healthy elderly participants, 21 (11M:10F) were
non-sarcopenic and had a mean age (±SD) of 79 ± 3.6years and a
BMI (±SD) of 25.4 ± 3.8, all were weight-stable and none had an
elevated serum C-reactive protein. Seven (4M:3F) of the healthy el-
derlywere sarcopenic and had amean age (±SD) of 80.3±3.9 years
and an average BMI (±SD) of 22.8 ± 2.6, and none had an elevated
serum C-reactive protein. The healthy middle-aged controls had a
mean age (±SD) of 61 ± 7 years. There was a predominance of
male participants, average BMI (±SD) was 24.2 ± 3.3, and all were
weight-stable. (Values are mean and SD, aDeﬁned by >10% WL,
bBaumgartner’s criteria).
96 J. Brzeszczyńska et al.
Journal of Cachexia, Sarcopenia and Muscle 2018; 9: 93–105
DOI: 10.1002/jcsm.12252
generation, we measured multiple transcriptional markers
compared with middle-aged controls. The expression of
markers indicating satellite cell activation, i.e., the muscle
transcription factor Pax7 was higher in HSE (4-fold,
P < 0.05) compared with HMC (Figure 1a). The expression
of markers of early differentiation (MyoD and Myf5) were
not signiﬁcantly increased in the HSE group when compared
with HMC (Figure 1b). However, in the HSE group elevated
expression of MyoG, a marker of terminal differentiation,
was found (6-fold, P < 0.01) (Figure 1c). In addition, in the
HSE group, the muscle remodelling factor Mef2 was signiﬁ-
cantly downregulated (Figure 1d) when compared with
HMC. In the series of human muscle biopsies, the expression
of the pro-apoptotic gene Bax (Figure 5a) was increased
in HENS compared with HMC (3-fold, P < 0.01). Bcl2
(Figure 5a) was increased in HENS (6-fold, P < 0.0001) and
HSE (4-fold, P < 0.05) compared with HMC.
With the in vitro system of myogenesis using human
skeletal muscle cells from donors of increasing age
(17–83 years), there was a reduction of the fusion index
calculated from myoblast cultures of younger (17–51 years)
and older (69–83 years) donors after 72 h of myogenic
differentiation (Figure 3a). In the older group, there was a
lower expression of both the differentiation marker MyoD
(P < 0.01) (Figure 3b) and the remodelling factor Mef2C
(P < 0.0001) (Figure 3c) when compared with the younger
group. In contrast, the expression of the differentiation
marker Myf5 was not altered. The expression of the late
myogenesis markers (MyoG, Troponin T1 (TNNT1)) were
Figure 1 Fold change in mRNA expression (±SD) of genes related to a.)
satellite cell activation, b.) myoblast proliferation/early differentiation,
c.) late myocyte/myotube differentiation, and d.) myotube remodelling
in the quadriceps muscle of Healthy Elderly Sarcopenic (HSE), Healthy El-
derly Non-Sarcopenic (HENS), and healthy middle-aged control (HMC)
groups: HMC (n = 22), HENS (n = 20), HSE (n = 7). Fold-change is relative
to HMC participants. Quantitative polymerase chain reaction results
show upregulation of mRNA levels of Pax3 (** P < 0.01 in HENS) and
Pax7 (**** P < 0.0001 in HENS; * P < 0.05 in HSE). Also, expression of
early myogenesis markers was increased: MyoD and Myogenic factor 5
(Myf5) (**** P < 0.0001 in HENS). mRNA of myogenin (MyoG) is upreg-
ulated in HENS (** P < 0.01) and in HSE (* P < 0.05). mRNA of remodel-
ling muscle marker myocyte enhancer factor-2 (Mef2) is downregulated
in HENS (** P < 0.01) and in HSE (* P < 0.05).
Figure 2 Fold change in mRNA expression (±SD) of genes of pro-inﬂam-
matory cytokines in the quadriceps muscle of Healthy Elderly Sarcopenic
(HSE), Healthy Elderly Non-Sarcopenic (HENS), and healthy middle-aged
control (HMC) groups: HMC (n = 22), HENS (n = 17), HSE (n = 7). Fold-
change of mRNA expression is relative to HMC participants. Quantitative
polymerase chain reaction show mRNA upregulation of TNF-α in HENS
(**** P < 0.0001). Also, expression of interleukin (IL)-6 in HENS and
HSE was markedly increased.
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Figure 3 In vitro system analysis of a.) fusion index presented as the percentage of nuclei in myotubes [myosin heavy chain positive (MHC) positive]
compared with the total number of nuclei of young and old donors after 72 h of myogenic differentiation b.) differences of early and late myogenesis
markers expression in young and old donors, c.) expression of myocyte enhancer factor 2 (Mef2) d.) expression analysis time course of differentiation
marker from a 17- and 83-year-old donor e.) semi-quantitative western blot analysis of activation of the p38 pathway in human skeletal muscle cells
from 17- and 83-year-old donor f.) cytokine expression analysis of young and old donors (myoblast) g.) level of cytokines secreted in the supernatant of
young and old donors after 48 h of differentiation h.) expression analysis of the senescence marker p16
INK4a
(Cdkn2) between young and old donors i.)
analysis of stress-pathway activation in young vs old donors. Myf5, Myogenic factor 5; MyoG, myogenin; IL, interleukin.
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reduced (P < 0.0001) in the older donor group compared
with the younger donor group (Figure 3b).
Detailed comparison of the myogenic process in a
young (17 years) and old (83 years) myoblast
donor
The early differentiation marker Myf5 showed the same ex-
pression pattern (signiﬁcant downregulation over time) in
both donors. However, MyoD expression was higher
(P < 0.01) in the young donor and not modulated over
the period of myogenesis. The most marked differences
were detected in the late differentiation markers MyoG
and TNNT1. In the young donor, 3-fold upregulation of
TNNT1 (P < 0.0001) and a 0.5-fold upregulation of MyoG
(P < 0.0001) was seen at 72 h compared with the old
donor (Figure 3d). The higher expression and secretion of
cytokines in hsKMC of the old donor was associated with
an increased activation of the p38 pathway throughout
the myogenesis process. Initial activation of the p38 path-
way (ﬁrst 3 h) was observed only in the young donor
(Figure 3e). However, the p38 pathway was activated in
the old donor and was detected through the whole differ-
entiation process starting at 1 h until myotube formation
at 72 h (Figure 3e).
Figure 3 (Continued)
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Inﬂuence of the muscle environment on ageing and
sarcopenic muscle
When compared with HMC, TNF-α was highly expressed
in the muscle of HENS (30-fold, P < 0.0001) but interleukin
(IL)-6 expression was not signiﬁcantly different (Figure 2).
In line with this ﬁnding, in the in vitro system, signiﬁcant
increases of IL-6, IL-8, and IL-1b were observed in the older
donor group (Figure 3f). Furthermore, an increase in ex-
pression of the senescence marker p16INK4a (Cdkn2) in the
older donor group was observed (Figure 3h) and was con-
sistent with the increased upregulation of cytokine expres-
sion. The higher expression of the senescence marker
p16INK4a could not be conﬁrmed in the muscle biopsies
(Figure 4).
The detection of elevated expression of cytokines in vitro
raised the question of whether this would translate to a higher
secretion of cytokines in the culture media. Analysis of the cell
supernatant at 48 h showed increases in the secretion of the
cytokines IL1a (P < 0.001), IL-6 (P < 0.001), IL-8 (P < 0.05),
and TNF-α (P< 0.001) in the older donor group comparedwith
the younger donor group (Figure 3g).
HSPA1A a response marker for misfolded proteins, was
upregulated 15-fold (P < 0.001) in HSE (Figure 5b) and 5-fold
(P < 0.01) in HENS compared with HMC. Oxidative stress
defence markers were also upregulated to a greater extent
in HENS compared with HSE. Nrf2 (Nuclear Factor, Erythroid
2 like2) was upregulated 25-fold (P < 0.001) in HENS and
12-fold (P < 0.01) in HSE when compared with HMC
(Figure 6). Expression of Sod2 (superoxide Dismutase 2) was
similar in all groups. Note that the in vitro data differed from
the in vivo data, i.e., no signiﬁcant old–young differences in
HSPA1A (Figure 3i) and the oxidative stress genes Nrf2 and
GCLM (Glutamate-Cysteine Ligase Modiﬁer Subunit) (data
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not shown), In contrast to the in vivo results in the in vitro
system, an upregulation in SOD2 could be shown (Figure 3i).
Discussion
We investigated whether myogenesis is altered in healthy el-
derly adults with or without sarcopenia, diagnosed according
to established criteria,21 compared with HMCs using both
in vivo and in vitro approaches. The main ﬁndings of this
study suggest that both pathological and adaptive processes
are active in skeletal muscle during healthy ageing, with
transcriptomic evidence of increased satellite cell activation.
Our data demonstrate that there is activation of countermea-
sures to oppose increased stress in older muscle cells, and
suggest that these countermeasures may also be altered in
sarcopenia. Our ﬁndings in young and old muscle are
consistent with some of the ﬁndings described using mouse
or rat in vivo models, including increased TNF-α and
myogenic markers.19 This study demonstrates the utility of
a combined in vivo and in vitro approach to the investigation
of the biology of healthy ageing with or without sarcopenia,
and suggests that the process of myogenesis may be altered
in sarcopenia.
Using myoblasts obtained from a number of donors
across the adult age range, the present study demonstrated
a decrease of myoblast fusion in older compared with young
Figure 3 (Continued)
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Figure 4 Fold change in mRNA expression (±SD) of senescence marker in
the quadriceps muscle of Healthy Elderly Sarcopenic (HSE), Healthy El-
derly Non-Sarcopenic (HENS), and healthy middle-aged control (HMC)
groups: HMC (n = 22), HENS (n = 15), HSE (n = 6). Quantitative polymer-
ase chain reaction show increasing trend of the master regulator of se-
nescence p16INK4a (Cdkn2) mRNA upregulation in HENS and HSE
muscles with no statistical signiﬁcance.
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donors. Moreover, myogenin and Troponin I transcription
were decreased in the myoblast cultures from the older do-
nors indicating reduced or impaired kinetics of myotube for-
mation. The expression of the master regulator of
senescence, p16INK4a (Cdkn2), was signiﬁcantly higher in
older donors (Figure 3h) as was the secretion of pro-
inﬂammatory cytokines. Elevation of inﬂammatory cytokines
has been demonstrated previously in human populations.25
Possibly such upregulation of pro-inﬂammatory cytokines
with age induces cellular senescence8,20 and is associated
with a reduced rate of differentiation in the myogenic path-
way. In addition, TNF-α is a key up-regulator of NF-kB and IL-
6, which increases the inﬂammatory response. This pathway
not only effectively enhances the death of existing muscle
ﬁbres but also inhibits the formation of new ﬁbres via MyoD
and Mef2 downregulation leading to the loss of skeletal
muscle mass and weakness.26,27 TNF and IL-6 are also
established components of the Senescence-Associated
Secretory Protein response; a set of cytokines secreted by
senescent cells that deregulate normal tissue function.
The HENS and HSE groups were all aged > 79 years, thus
the effect of older age per se can be inferred by comparison
of HENS with the HMC group, whereas changes either
resulting from or causing sarcopenia can be assessed by
comparison with the HENS and HSE groups. Satellite cell
activation transcriptional factors were expressed to a greater
degree in the muscles of both HENS and HSE compared with
HMC suggesting activation of this pathway in older age. In
contrast, signiﬁcant expression of early myogenesis markers
(Myf5 and MyoD), indicative of an orderly pattern of
myogenesis, was found only in the HENS group suggesting a
possible alteration in the progress of myogenesis associated
with sarcopenia. Signiﬁcantly, 30-fold increased expression
of TNF-α was detected in the muscles of HENS but not HSE
when compared with HMC. These ﬁndings might suggest a
paradoxical role of TNF-α in ageing muscle maintenance.28
Alternatively, the active inﬂammatory phase of muscle loss
may occur before clinical sarcopenia is detected (that is, in
HENS); by the time clinical sarcopenia is detected using body
composition and/or physical function, a more ﬁbrotic process
is in play and TNF-α is no longer elevated. The muscle remod-
elling factor Mef2 was downregulated in both HENS and HSE,
and this may relate to increased pro-inﬂammatory cytokine
expression1 or other regulatory factors. In contrast with our
ﬁndings in vitro where terminal differentiation was delayed/
impaired, in vivo the terminal differentiation marker MyoG
demonstrated similar increased expression in both HSE and
HENS compared with HMC. This result implies that in vivo:
(a) the regeneration process is activated and has the
potential to progress to completion in old age, (b) the ob-
served alterations in early myogenesis transcription pathways
associated with sarcopenia do not necessarily lead to a
Figure 5 Fold change in mRNA expression (±SD) of a) mitochondrial factors Bax and Bcl2, b) misfolded proteins (Hsp1) pathways in the quadriceps
muscle of Healthy Elderly Sarcopenic (HSE), Healthy Elderly Non-Sarcopenic (HENS), and healthy middle-aged control (HMC) groups: HMC (n = 22),
HENS (n = 17), HSE (n = 6). Fold-change of mRNA expression is relative to HMC. Quantitative polymerase chain reaction results show upregulation
of mitochondrial factors Bax (** P < 0.01) in HENS participants and signiﬁcantly higher upregulation of Bcl2 (**** P < 0.0001) in HENS and (*
P < 0.05) in HES. b) mRNA of Hsp1 is upregulated in HSE (*** P < 0.001) and in HENS (** P < 0.01).
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block in ﬁnal myotube differentiation. To what extent changes
in MyoGmRNA level actually reﬂect the overall differentiation
achieved in vivo cannot be determined from the present data.
Although the expression of the senescence marker
p16INK4a (Cdkn2) increased with the donor age in vitro, this
ﬁnding was not observed in vivo. It is possible that we may
have captured only a very small proportion of senescent mus-
cle cells compared with other muscle cell types in the muscle
sample. Caution is needed when comparing data from cells
in vitro with ageing cells in vivo: The interrelationship and
complexity of factors in an in vivo environment that dictate
the behaviour and fate of a senescent cell and that inﬂuence
the recruitment of stem cells into the myogenic lineage still
require further investigation.
Cellular senescence is also associated with elevated ROS
production, apoptosis, and increased oxidative and glycation
damage.29 In the present study, we detected activation of
the cellular anti-oxidant defence pathway Nrf2 in the muscles
of both HENS and HSE when compared with HMC. In HSE, the
upregulation of Nrf2 was reduced compared with HENS and
the Nrf2 downstream gene Gclm was upregulated only in
HENS. Thus, although old age seems to be associated with ac-
tivation of oxidative defence, the presence of sarcopenia is
possibly associated with a less vigorous response. It is of in-
terest that HSPA1A (Hsp70) expression was increased in both
HENS and HSE compared with HMC, but to a greater extent in
HSE, suggesting that misfolded protein stress is increased
with advancing age but may be greater in sarcopenia. Re-
duced cellular defence markers and increased level of
misfolded proteins in HSE muscle may contribute to intracel-
lular accumulation of ROS, which may negatively impact on
the regeneration process.30 In the present study, signiﬁcant
upregulation of the mitochondrial factors, Bax, and Bcl2 in
HENS and HSE, also may indicate increased intracellular stress
in elderly adults. For HSPA1A and Sod2, again, our in vitro
system yielded different results compared with the
in vivo analysis, reﬂecting not only the complexity of
the in vivo environment as explained earlier, but also due to
cells being cultured in vitro under optimal conditions within
a system representing the earlier stages of regeneration,
making it more unlikely that (for HSPA1A) we would see up-
regulation of the misfolded protein response.
The present study assessed mainly transcriptomic markers
of muscle regeneration under basal conditions (at rest, after
fasting) and may not reﬂect the complexity of day to day
living. Although the in vitro system has the advantage of
a uniform cell population; clearly, it is only a snapshot of a
process that in vivo has a much longer timescale. Equally,
muscle biopsies are not of single cell origin and some of
the changes observed may be ascribed to cells other than
those of myocellular lineage. Moreover, data from the biop-
sies does not discriminate cause from effect. We were unable
to compare protein signatures obtained in the elderly groups
with the healthy middle age group due to the limited size of
samples from HMC. A disadvantage of the in vivo study was
the comparison between different ages rather than differ-
ences in age matched controls. Moreover, the sample size
particularly in the HSE group was small. Future studies in
larger cohorts would be valuable to conﬁrm our ﬁndings.
Furthermore, studies comparing responses of healthy elderly
adults with or without sarcopenia to exercise training, which
has profound effects on satellite cell function, muscle
Figure 6 Fold change in mRNA expression (±SD) of oxidative defence
genes Sod2, Gclm, and Nrf2 in the quadriceps muscle of Healthy Elderly
Sarcopenic (HSE), Healthy Elderly Non-Sarcopenic (HENS), and healthy
middle-aged control (HMC) groups: HMC (n = 22), HENS (n = 18), HSE
(n = 7); fold-change of mRNA expression is relative to HMC participants.
mRNA expression of the oxidative defence genes is increased mainly in
HENS (Nrf2 **** P < 0.0001, Gclm*** P < 0.001) but also in HSE (Nrf2
** P < 0.01) when compared with HMC. Similarly, Sod2 and Gclm had
lower expression level in HSE when compared with HMC.
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regeneration markers activation or mitochondrial ROS pro-
duction in muscle are recommended.
In summary, our study demonstrates that both pathologi-
cal and adaptive processes are active in skeletal muscle
during healthy ageing and are maintained even with
sarcopenia, although we suggest that failure of speciﬁc
adaptive processes may underlie the development of
sarcopenia. Muscle regeneration pathways are activated in
the healthy ageing elderly without sarcopenia, but may be
dysregulated or simply overwhelmed in sarcopenic elderly
people. Further understanding of the pathway regulation of
activated satellite cell function may be a potentially promis-
ing avenue for the identiﬁcation of strategies to promote
healthy ageing and combat sarcopenia.
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